Spondyloarthropathies News

Upadacitinib sustains its efficacy in non-radiographic axial spondyloarthritis through 2 years without presenting any new safety signals, according to data published in Arthritis Research & Therapy.

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according to data published in The Lancet Rheumatology.

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% compared with NSAIDs, according to data published in Arthritis & Rheumatology.

Depression and anxiety among patients with inflammatory arthritis is significantly undertreated, with large proportions not receiving minimally adequate care, according to data published in Arthritis Research & Therapy.

Targeted therapies for active inflammatory arthritis should be started “without delay” for patients with cancer in remission, according to new EULAR points to consider published in Annals of the Rheumatic Diseases.

Women with axial spondyloarthritis face longer diagnostic delays and greater disease burden than men despite higher rates of treatment and healthy behaviors, according to data published in International Journal of Rheumatic Diseases.

Individuals with spondyloarthritis can reduce their number of rheumatology visits through patient-initiated follow-up with asynchronous telehealth, without sacrificing outcomes, according to data published in The Lancet Rheumatology.

WASHINGTON — Patients with autoimmune rheumatic diseases who withhold methotrexate for 2 weeks after receiving the recombinant herpes zoster vaccine demonstrate improved humoral response, according to data presented at ACR Convergence 2024.